Over $500 Million Worldwide Tumor Ablation Therapy Device Industry By 2031 – Rising Cancer Prevalence Is A Driver – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The report “Global Tumor Ablation Therapy Devices Market Report 2022” has been added to ResearchAndMarkets.com offer.

This report provides strategists, marketers and senior management with the critical information they need to evaluate the global tumor ablation therapy device market.

The global tumor ablation therapy devices market is expected to grow from USD 0.49 billion in 2021 to USD 0.56 billion in 2022 at a compound annual growth rate (CAGR) of 14.1%. The market is expected to grow to $0.97 billion by 2026 at a compound annual growth rate (CAGR) of 15%.

Mentioned Companies

  • Galil Medical Inc.

  • Misonix Inc.

  • HealthTronics

  • angiodynamics

  • boston scientific corporation

  • Medtronic Plc.

  • EDAP TMS SA

  • Neuwave Medical Inc.

  • BVM Medical Limited

  • Heritage Electromedicine GmbH

  • BTG International Ltd.

  • AtriCure, Inc.

  • theraclion

  • INTIO Inc.

reasons to buy

  • Gain a truly global perspective with the most comprehensive report available in this market, covering 12+ geographic regions

  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus subsides

  • Create regional and national strategies based on local data and analysis

  • Identify growth segments for investment

  • Outperform competitors using forecast data and the drivers and trends shaping the market

  • Understand customers based on the latest market research findings

  • Benchmark performance against major competitors

  • Utilize relationships across key datasets for superior strategy

  • Suitable to support your internal and external presentations with reliable high quality data and analytics

The tumor ablation therapy device market consists of sales of tumor ablation devices and related services used in hospitals and oncology clinics. Tumor ablation is the technique used to extract tumors by means of a needle, to insert them into the tumor organ by means of imaging techniques.

The main technologies in tumor ablation therapy devices are radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, among others. Irreversible electroporation (IRE) in tumor ablation therapy is a new tissue ablation method in which micro- to millisecond electrical pulses are delivered to unwanted tissues to produce cell necrosis by irreversible cell membrane permeabilization. Included treatments are surgical, laparoscopic and percutaneous which are used in various applications like kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer and others. The various end users of tumor ablation therapy devices are hospitals, oncology clinics and others.

North America was the largest region in the market for tumor ablation therapy devices in 2021. Asia Pacific was the second largest region in the market for tumor ablation therapy devices. The regions covered in this report are Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The rising prevalence of cancer is a key factor driving the growth of the tumor ablation therapy device market. Cancer is considered the second leading cause of death with around 1 in 6 deaths due to cancer worldwide. Tumor ablation is a minimally invasive procedure widely used in the treatment of lung, liver, kidney and bone tumors.

Product recalls of tumor ablation devices due to technical issues are expected to hinder the growth of the tumor ablation therapy device market. Companies are withdrawing their products from the market for safety reasons.

For example, the Covidien Emprint Long Percutaneous Antenna with Thermosphere Technology, a tumor ablation device from Medtronic withdrew its devices due to the Emprint ablation ceramic trocar tip disengaging from the needle shaft after ablation. Similarly, in June 2018, the Medtronic Sofamor Danek USA Inc Accurian RF Ablation was recalled due to difficulty in insertion. Product recalls have placed a financial burden on companies hampering the market for tumor ablation therapy devices.

Leading companies operating in tumor ablation therapy devices are focusing on technological advances for shorter procedures, greater safety, less radiation exposure, faster learning curves and better results J&J medicals has launched a micro ablation system -waves called NEUWAVE, which is the first device to put electrodes on cancer cells and thus increase the temperature around them to burn the cancer cells.

The countries covered in the tumor ablation therapy device market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

For more information on this report, visit https://www.researchandmarkets.com/r/xgg89p

Over $500 Million Worldwide Tumor Ablation Therapy Device Industry By 2031 – Rising Cancer Prevalence Is A Driver – ResearchAndMarkets.com

Leave a Reply

Your email address will not be published.

Scroll to top